These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 19557769

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
    Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J.
    Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
    [Abstract] [Full Text] [Related]

  • 4. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not.
    Tefferi A, Mesa RA, Pardanani A, Hussein K, Schwager S, Hanson CA, Steensma DP.
    Am J Hematol; 2009 May; 84(5):265-7. PubMed ID: 19396855
    [Abstract] [Full Text] [Related]

  • 5. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
    Leitch HA, Parmar A, Wells RA, Chodirker L, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating MM, Sabloff M, St Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Kew A, Shamy A, Elemary M, Lenis M, Mamedov A, Ivo J, Francis J, Zhang L, Buckstein R.
    Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
    [Abstract] [Full Text] [Related]

  • 6. Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis.
    Leitch HA, Chan C, Leger CS, Foltz LM, Ramadan KM, Vickars LM.
    Leuk Res; 2012 Nov; 36(11):1380-6. PubMed ID: 22921191
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies.
    Kim YR, Kim JS, Cheong JW, Song JW, Min YH.
    Acta Haematol; 2008 Nov; 120(3):182-9. PubMed ID: 19129689
    [Abstract] [Full Text] [Related]

  • 9. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype.
    Tefferi A, Siragusa S, Hussein K, Schwager SM, Hanson CA, Pardanani A, Cervantes F, Passamonti F.
    Am J Hematol; 2010 Jan; 85(1):14-7. PubMed ID: 20029953
    [Abstract] [Full Text] [Related]

  • 10. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis.
    Pardanani A, Finke C, Abdelrahman RA, Lasho TL, Tefferi A.
    Am J Hematol; 2013 Apr; 88(4):312-6. PubMed ID: 23450619
    [Abstract] [Full Text] [Related]

  • 11. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy.
    Wong CAC, Wong SAY, Leitch HA.
    Leuk Res; 2018 Apr; 67():75-81. PubMed ID: 29477023
    [Abstract] [Full Text] [Related]

  • 12. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M, Selleslag D, Triffet A, Mineur P, Bries G, Graux C, Trullemans F, MacDonald K, Abraham I, Pluymers W, Ravoet C.
    Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
    [Abstract] [Full Text] [Related]

  • 13. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.
    Chacko J, Pennell DJ, Tanner MA, Hamblin TJ, Wonke B, Levy T, Thomas PW, Killick SB.
    Br J Haematol; 2007 Sep; 138(5):587-93. PubMed ID: 17610536
    [Abstract] [Full Text] [Related]

  • 14. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution.
    Tefferi A, Huang J, Schwager S, Li CY, Wu W, Pardanani A, Mesa RA.
    Cancer; 2007 May 15; 109(10):2083-8. PubMed ID: 17407134
    [Abstract] [Full Text] [Related]

  • 15. Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
    Wong SA, Leitch HA.
    Leuk Res; 2018 Jan 15; 64():24-29. PubMed ID: 29149650
    [Abstract] [Full Text] [Related]

  • 16. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival.
    Patnaik MM, Caramazza D, Gangat N, Hanson CA, Pardanani A, Tefferi A.
    Eur J Haematol; 2010 Feb 01; 84(2):105-8. PubMed ID: 19895568
    [Abstract] [Full Text] [Related]

  • 17. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
    Remacha AF, Arrizabalaga B, Del Cañizo C, Sanz G, Villegas A.
    Ann Hematol; 2010 Feb 01; 89(2):147-54. PubMed ID: 19690857
    [Abstract] [Full Text] [Related]

  • 18. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
    Lee SE, Yahng SA, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Kim HJ, Cho SG, Kim DW, Min WS, Park CW, Lee JW.
    Acta Haematol; 2013 Feb 01; 129(2):72-7. PubMed ID: 23154600
    [Abstract] [Full Text] [Related]

  • 19. Early massive transfusion in trauma patients: Canadian single-centre retrospective cohort study.
    Mahambrey TD, Fowler RA, Pinto R, Smith TS, Callum JL, Pisani NS, Rizoli SB, Adhikari NK.
    Can J Anaesth; 2009 Oct 01; 56(10):740-50. PubMed ID: 19641979
    [Abstract] [Full Text] [Related]

  • 20. [Clinical features and prognostic factors in primary myelofibrosis patients under 45 years old].
    Lu L, Xiao ZJ, Chen HS, Lin H, Han ZC.
    Zhonghua Xue Ye Xue Za Zhi; 2005 May 01; 26(5):281-4. PubMed ID: 15949290
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.